title: Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: A case report.
authors.affiliation: Department of Dermatology, Fujita Health University School of Medicine, Toyoake, Japan.
authors.forename: Shigeki
authors.initials: S
authors.lastname: Numata
authors.affiliation: Department of Dermatology, Fujita Health University School of Medicine, Toyoake, Japan.
authors.forename: Yohei
authors.initials: Y
authors.lastname: Iwata
authors.affiliation: Department of Dermatology, Fujita Health University School of Medicine, Toyoake, Japan.
authors.forename: Rie
authors.initials: R
authors.lastname: Okumura
authors.affiliation: Department of Dermatology, Fujita Health University School of Medicine, Toyoake, Japan.
authors.forename: Masaru
authors.initials: M
authors.lastname: Arima
authors.affiliation: Department of Dermatology, Fujita Health University School of Medicine, Toyoake, Japan.
authors.forename: Tsukane
authors.initials: T
authors.lastname: Kobayashi
authors.affiliation: Department of Dermatology, Fujita Health University School of Medicine, Toyoake, Japan.
authors.forename: Soichiro
authors.initials: S
authors.lastname: Watanabe
authors.affiliation: Department of Ophthalmology, Fujita Health University School of Medicine, Toyoake, Japan.
authors.forename: Keita
authors.initials: K
authors.lastname: Suzuki
authors.affiliation: Department of Ophthalmology, Fujita Health University School of Medicine, Toyoake, Japan.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Horiguchi
authors.affiliation: Department of Dermatology, Fujita Health University School of Medicine, Toyoake, Japan.
authors.forename: Kazumitsu
authors.initials: K
authors.lastname: Sugiura
mesh_terms: D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors / Q000276:immunology; D005158:Facial Paralysis / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis; D015804:HLA-DR4 Antigen / Q000097:blood / Q000276:immunology; D006801:Humans; D000074324:Ipilimumab / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D000077594:Nivolumab / Q000009:adverse effects; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology; D014606:Uveitis, Anterior / Q000097:blood / Q000175:diagnosis / Q000276:immunology* / Q000473:pathology
chemical_list: D000074322:Antineoplastic Agents, Immunological; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D015804:HLA-DR4 Antigen; D000074324:Ipilimumab; D000077594:Nivolumab